Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer

Clinical Trials

Volumn 5, Issue 3, 2008, Pages 262-272

  Demark Wahnefried, Wendy ^a   George, Stephen L ^b   Switzer, Boyd R ^c   Snyder, Denise C ^d   Madden, John F ^b   Polascik, Thomas J ^b   Ruffin, Mack T ^e   Vollmer, Robin T ^b,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c IL   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; PLACEBO; TUMOR MARKER;

ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG URINE LEVEL; EJACULATION; HEALTH SURVEY; HUMAN; HUMAN TISSUE; LINSEED; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; DIET THERAPY; FAT INTAKE; FLAX; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PROSTATE TUMOR; STATISTICAL MODEL;

CLINICAL TRIALS, PHASE II AS TOPIC; DIETARY FATS; FLAX; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 54549086661     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774508091676     Document Type: Article

References (48)

1. Bostwick DG, Burke HB, Djakiew D., et al. Human prostate cancer risk factors. Cancer 2004; 101 (10 Suppl): 2371-490.
2. Kushi LH, Byers T., Doyle C., et al. American cancer society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2006; 56: 254-81.
3. Lippman SM, Goodman PJ, Klein EA, et al. Designing the selenium and vitamin E cancer prevention trial (SELECT). J Natl Cancer Inst 2005; 97: 94-102.
4. Lee JJ, Lieberman R., Sloan JA, et al. Design considerations for efficient prostate cancer chemoprevention trials. Urol 2001; 57 (4 Suppl 1): 205-12.
5. Thompson IM, Tangen CM, Klein EA, et al. Phase III prostate cancer prevention trials: Are the costs justified? J Clin Oncol 2005; 23: 8161-64.
6. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res 2003; 9: 502S-10S.
7. Kim J., Sun P., Lam YW, et al. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1697-702.
8. Adlercreutz H. Epidemiology of phytoestrogens. Baillieres Clin Endocrinol Metab 1998; 12: 605-23.
9. Freeman VL, Meydani M., Hur K., Flanigan RC Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma. Cancer 2004; 101: 2744-54.
10. Griffiths K., Denis L., Turkes A., Morton MS Phytoestrogens and diseases of the prostate gland. Baillieres Clin Endocrinol Metab 1998; 12: 625-47.
11. Morton MS, Turkes A., Denis L., Griffiths K. Can dietary factors influence prostatic disease? BJU Int 1999; 84: 549-54.
12. Ritch CR, Wan RL, Stephens LB, et al. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J Urol 2007; 177: 97-101.
13. Webb AL, McCullough ML Dietary lignans: Potential role in cancer prevention. Nutr Cancer 2005; 51: 117-31.
14. Lands WE, Libelt B., Morris A. Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids. Biochim Biophys Acta 1992; 1180: 147-62.
15. Lin X., Switzer BR, Demark-Wahnefried W. Effect of mammalian lignans on the growth of prostate cancer cell lines. Anticancer Res 2001; 21(6A): 3995-99.
16. Lin X., Gingrich JR, Bao W., et al. Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urol 2002; 60: 919-24.
17. Demark-Wahnefried W., Robertson CN, Walther PJ Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urol 2004; 63: 900-04.
18. Bostwick DG, Aquilina JW Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. J Cell Biochem Suppl 1996; 25: 156-64.
19. Allam CK, Bostwick DG, Hayes JA Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. Mod Pathol 1996; 9: 742-51.
20. Wills ML, Hamper UM, Partin AW, Epstein JI Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urol 1997; 49: 367-73.
21. Demark-Wahnefried W., Price DT, Polascik TJ, et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: Exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urol 2001; 58: 47-52.
22. Simon R., Freedman LS Bayesian design and analysis of two × two factorial clinical trials. Biometr 1997; 53: 456-64.
23. Shultz TD, Howie BJ In vitro binding of steroid hormones by natural and purified fibers. Nutr Cancer 1986; 8: 141-47.
24. Bostwick DG, Montironi R., Nogle R., et al. Current and proposed biologic markers in prostate cancer. J Cell Biochem Suppl 1992; 16H: 65-67.
25. Kucuk O. Chemoprevention of prostate cancer. Cancer Metastasis Rev 2002; 21: 111-24.
26. Bloedon LT, Szapary PO Flaxseed and cardiovascular risk. Nutr Rev 2004; 62(1): 18-27.
27. Hager MH, Solomon KR, Freeman MR The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 2006; 9: 379-85.
28. Kasim-Karakas SE, Tsodikov A., Singh U. Responses of inflammatory markers to a low-fat, high-carbohydrate diet: Effects of energy intake. Am J Clin Nutr 2006; 83: 774-79.
29. Sonn GA, Aronson W., Litwin MS Impact of diet on prostate cancer: A review. Prostate Cancer Prostat Dis 2005; 8: 304-10.
30. Hamalainen EK, Adlercreutz H., Puska P. Decrease of serum total and free testosterone during a low-fat high-fibre diet. J Steroid Biochem 1983; 18: 369-70.
31. Machin DCM. Statistical tables for the design of clinical trials, 2nd edn. Blackwell, Oxford, 1996.
32. Polascik TJ, Oesterling JE, Partin AW Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol 1999; 162: 293-306.
33. Bligh EG, Dyer WJ A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-17.
34. Morton MS, Chan PS, Cheng C. Lignans and isoflavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997; 32: 122-28.
35. Lampe JW, Martini MC, Kurzer MS Urinary lignan and isoflavonoid excretion in premenopausal women consuming flaxseed powder. Am J Clin Nutr 1994; 60: 122-28.
36. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005; 174: 919-22.
37. Subar AF, Thompson FE, Kipnis V., et al. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: The Eating at America's Table Study. Am J Epidemiol 2001; 154: 1089-99.
38. Thompson FE, Subar AF, Brown CC, et al. Cognitive research enhances accuracy of food frequency questionnaire reports: Results of an experimental validation study. J Am Diet Assn 2002; 102: 212-25.
39. Kohl HW, Blair SN, Paffenbarger Jr RS A mail survey of physical activity habits as related to measured physical fitness. Am J Epidemiol 1988; 127: 1228-39.
40. Thompson LU Experimental studies on lignans and cancer. Baillieres Clin Endocrinol Metab 1998; 12: 691-705.
41. Stasse-Wolthuis M., Hautvast JG, Hermus RJ, et al. The effect of a natural high-fiber diet on serum lipids, fecal lipids, and colonic function. Am J Clin Nutr 1979; 32: 1881-88.
42. Farmer KC Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Therapeut 1999; 21: 1074-90.
43. Rogatko A., Babb JS, Wang H. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res. 2004; 10: 4645-51.
44. Tateyama H., Tada T., Hattori H., et al. Effects of prefixation and fixation times on apoptosis detection by in situ end-labeling of fragmented DNA. Arch Pathol Lab Med 1998; 122: 252-55.
45. Tefilli MV, Gheiler EL, Tiguert R., et al. Should Gleason score 7 prostate cancer be considered a unique grade category? Urol 1999; 53: 372-77.
46. Rojavin MA Recruitment index as a measure of patient recruitment activity in clinical trials. Contemp Clin Trials 2005; 26: 552-56.
47. Bolen S., Tilburt J., Baffi C., et al. Defining "success" in recruitment of underrepresented populations to cancer clinical trials: moving toward a more consistent approach. Cancer 2006; 106: 1197-204.
48. American Cancer Society. Cancer Facts and Figures, 2007. ACS, Atlanta, 2007.